Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00060684 · ClinicalTrials.gov registry record · Phase 1

Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma

A Phase 1 study, sponsored by CTI BioPharma.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target

NCT00060684: Completed Phase 1 study, sponsored by CTI BioPharma.

NCT00060684 is a Phase 1 study that has completed, run by CTI BioPharma. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT00060684, a Phase 1 study, has completed, sponsored by CTI BioPharma.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target

Study Summary

The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

Interventions

  • DRUG fludarabine
  • DRUG dexamethasone
  • DRUG rituximab
  • DRUG Pixantrone (BBR 2778)

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2001-12
Est. Completion 2007-05
Phase Phase 1
CTI BioPharma

28 total trials

What the finished NCT00060684 record still lists

NCT00060684 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 4 interventions - of which fludarabine is the first listed.

NCT00060684 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00060684 about?

NCT00060684 is a clinical study titled "Dose Ranging Trial for Pixantrone in the FND-R Variant Regimen in Indolent Non-Hodgkin's Lymphoma". The aim of this trial is to determine the appropriate dose of pixantrone to be used in this combination and obtain data on the combination's safety and activity profile.

What is the current status of trial NCT00060684?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2001-12. Estimated completion is 2007-05.

What interventions are being tested in trial NCT00060684?

The interventions under investigation include: fludarabine (DRUG), dexamethasone (DRUG), rituximab (DRUG), Pixantrone (BBR 2778) (DRUG).

Who is sponsoring clinical trial NCT00060684?

This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.

Learn More About Clinical Trials

How this trial's enrollment target compares

Where NCT00060684's enrollment target sits among peer trials

30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00060684, the US trial registry maintained by the National Library of Medicine. NCT00060684 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.